Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities
Valby, Denmark, 13 May 2016 - H. Lundbeck A/S (Lundbeck) hereby reports transactions made by executives and persons and legal entities closely associated to them with shares and linked securities in Lundbeck, cf. Section 28a of the Danish Securities Trading Act.
On Lundbeck’s Annual General Meeting held on 31 March 2016, the shareholders authorized the board of directors to offer the CEO to participate in the 2014 warrant program. In connection herewith, the Board of Directors has granted the below warrants to the CEO, and the CEO has accepted to receive such warrants. Each warrant grants the right to subscribe for one (1) share in Lundbeck. The calculation of the market price of the warrants is based on Black-Scholes.
| Name: | Kåre Schultz |
| Job position: | President and CEO |
| ID code (ISIN code): | DK 0010287234 |
| Name of the issuer of the securities: | H. Lundbeck A/S |
| Description of the security: | Warrants |
| Nature of the transaction: | Grant of warrants |
| Date of trading (date of accept): | 12 May 2016 |
| Market on which the trading was affected: | Nasdaq OMX Copenhagen |
| Number of traded securities (warrants granted): | 400,000 |
| Market price of securities traded (Black-Scholes): | Approx. DKK 34.1 million |
Persons under obligation to report such transactions are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities could include but is not limited to:
• spouse or cohabitant
• children below the age of 18, provided that the executive is the custody holder
• legal entities in which the executive has a controlling influence
Lundbeck contacts
| Investors: | Media: |
| Palle Holm Olesen | Mads Kronborg |
| Vice President, Investor Relations | Senior Director, Corp. Communication |
| palo@lundbeck.com | mavk@lundbeck.com |
| +45 30 83 24 26 | +45 36 43 30 00 |
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this Progress in Mind.
Our approximately 5,300 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 2 billion; USD 2.2 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.